Huntsworth (LON:HNT)‘s stock had its “buy” rating reissued by equities research analysts at Liberum Capital in a research report issued to clients and investors on Friday, ThisIsMoney.Co.Uk reports.

A number of other analysts also recently commented on the stock. Berenberg Bank reissued a “buy” rating on shares of Huntsworth in a report on Thursday, October 10th. Peel Hunt reaffirmed a “buy” rating on shares of Huntsworth in a report on Tuesday, October 8th. Finally, Peel Hunt reaffirmed a “buy” rating and issued a GBX 135 ($1.76) price target on shares of Huntsworth in a report on Tuesday, October 1st. Five equities research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus target price of GBX 136 ($1.78).

HNT stock opened at GBX 87 ($1.14) on Friday. The company has a market cap of $321.99 million and a P/E ratio of 27.19. Huntsworth has a 52 week low of GBX 76.60 ($1.00) and a 52 week high of GBX 116 ($1.52). The company’s 50-day moving average price is GBX 88.24 and its 200 day moving average price is GBX 93.67. The company has a current ratio of 1.19, a quick ratio of 1.10 and a debt-to-equity ratio of 73.94.

About Huntsworth

Huntsworth plc, together with its subsidiaries, operates as a healthcare and communications company in the United Kingdom and rest of Europe, the United States, and internationally. The company operates through four divisions: Medical, Marketing, Immersive, and Communications. The Medical division provides scientific strategy and communications, publications planning and delivery, specialized medical writing, medical education, and payer and value communications services, as well as support services for internal medical teams.

Further Reading: What are popular range trading strategies?

Analyst Recommendations for Huntsworth (LON:HNT)

Receive News & Ratings for Huntsworth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Huntsworth and related companies with MarketBeat.com's FREE daily email newsletter.